0000073290 2026-06-01 2026-08-31 0000073290 2026-10-15 0000073290 2026-08-31 0000073290 2026-05-31 0000073290 us-gaap:RelatedPartyMember 2026-08-31 0000073290 us-gaap:RelatedPartyMember 2026-05-31 0000073290 us-gaap:SeriesAPreferredStockMember 2026-08-31 0000073290 us-gaap:SeriesAPreferredStockMember 2026-05-31 0000073290 2025-06-01 2025-08-31 0000073290 us-gaap:CommonStockMember 2026-05-31 0000073290 us-gaap:AdditionalPaidInCapitalMember 2026-05-31 0000073290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-05-31 0000073290 us-gaap:RetainedEarningsMember 2026-05-31 0000073290 us-gaap:CommonStockMember 2025-05-31 0000073290 us-gaap:AdditionalPaidInCapitalMember 2025-05-31 0000073290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-05-31 0000073290 us-gaap:RetainedEarningsMember 2025-05-31 0000073290 2025-05-31 0000073290 us-gaap:CommonStockMember 2026-06-01 2026-08-31 0000073290 us-gaap:AdditionalPaidInCapitalMember 2026-06-01 2026-08-31 0000073290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-06-01 2026-08-31 0000073290 us-gaap:RetainedEarningsMember 2026-06-01 2026-08-31 0000073290 us-gaap:CommonStockMember 2025-06-01 2025-08-31 0000073290 us-gaap:AdditionalPaidInCapitalMember 2025-06-01 2025-08-31 0000073290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-01 2025-08-31 0000073290 us-gaap:RetainedEarningsMember 2025-06-01 2025-08-31 0000073290 us-gaap:CommonStockMember 2026-08-31 0000073290 us-gaap:AdditionalPaidInCapitalMember 2026-08-31 0000073290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-08-31 0000073290 us-gaap:RetainedEarningsMember 2026-08-31 0000073290 us-gaap:CommonStockMember 2025-08-31 0000073290 us-gaap:AdditionalPaidInCapitalMember 2025-08-31 0000073290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-08-31 0000073290 us-gaap:RetainedEarningsMember 2025-08-31 0000073290 2025-08-31 0000073290 2023-09-28 2023-09-28 0000073290 2024-05-10 2024-05-10 0000073290 2024-05-31 0000073290 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-09-24 2026-09-24 0000073290 BMRA:ATMOfferingMember 2026-06-01 2026-08-31 0000073290 BMRA:ATMOfferingMember 2026-08-31 0000073290 BMRA:OneKeyCustomersMember srt:AsiaMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-06-01 2026-08-31 0000073290 BMRA:OneKeyCustomersMember srt:AsiaMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-06-01 2025-08-31 0000073290 BMRA:ThreeKeyCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2026-06-01 2026-08-31 0000073290 BMRA:ThreeKeyCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-06-01 2026-05-31 0000073290 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember BMRA:OneKeyVendorMember 2025-06-01 2025-08-31 0000073290 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember BMRA:OneVendorMember 2025-06-01 2025-08-31 0000073290 BMRA:AccountsPayablesMember us-gaap:SupplierConcentrationRiskMember BMRA:OneVendorMember 2026-06-01 2026-08-31 0000073290 BMRA:AccountsPayablesMember us-gaap:SupplierConcentrationRiskMember BMRA:TwoVendorsMember 2025-06-01 2026-05-31 0000073290 srt:MinimumMember 2026-08-31 0000073290 srt:MaximumMember 2026-08-31 0000073290 us-gaap:PropertyPlantAndEquipmentMember 2026-06-01 2026-08-31 0000073290 us-gaap:PropertyPlantAndEquipmentMember 2025-06-01 2025-08-31 0000073290 BMRA:MarketingAndDistributionRightsMember 2026-08-31 0000073290 BMRA:PurchasedTechnologyRightsMember 2026-08-31 0000073290 us-gaap:PatentsMember 2026-08-31 0000073290 BMRA:PolishDistributorMember 2026-08-31 0000073290 srt:ChiefExecutiveOfficerMember 2026-05-29 2026-05-29 0000073290 srt:MinimumMember 2026-05-31 0000073290 srt:MaximumMember 2026-05-31 0000073290 2025-06-01 2026-05-31 0000073290 BMRA:PolishDistributorMember 2026-05-31 0000073290 BMRA:ConsultingAgreementMember 2026-06-01 2026-08-31 0000073290 us-gaap:RestrictedStockUnitsRSUMember 2026-06-01 2026-08-31 0000073290 us-gaap:RestrictedStockUnitsRSUMember 2025-06-01 2025-08-31 0000073290 BMRA:ClinicalLabMember 2026-06-01 2026-08-31 0000073290 BMRA:ClinicalLabMember 2025-06-01 2025-08-31 0000073290 BMRA:OverTheCounteMember 2026-06-01 2026-08-31 0000073290 BMRA:OverTheCounteMember 2025-06-01 2025-08-31 0000073290 BMRA:ContractManufacturingMember 2026-06-01 2026-08-31 0000073290 BMRA:ContractManufacturingMember 2025-06-01 2025-08-31 0000073290 BMRA:PhysiciansOfficeMember 2026-06-01 2026-08-31 0000073290 BMRA:PhysiciansOfficeMember 2025-06-01 2025-08-31 0000073290 country:MX 2026-08-31 0000073290 country:MX 2026-05-31 0000073290 srt:AsiaMember 2026-06-01 2026-08-31 0000073290 srt:AsiaMember 2025-06-01 2025-08-31 0000073290 srt:NorthAmericaMember 2026-06-01 2026-08-31 0000073290 srt:NorthAmericaMember 2025-06-01 2025-08-31 0000073290 srt:EuropeMember 2026-06-01 2026-08-31 0000073290 srt:EuropeMember 2025-06-01 2025-08-31 0000073290 us-gaap:MiddleEastMember 2026-06-01 2026-08-31 0000073290 us-gaap:MiddleEastMember 2025-06-01 2025-08-31 0000073290 srt:SouthAmericaMember 2026-06-01 2026-08-31 0000073290 srt:SouthAmericaMember 2025-06-01 2025-08-31 0000073290 BMRA:BuildingInIrvineCaliforniaMember 2026-08-31 0000073290 2016-11-01 2016-11-30 0000073290 2016-11-30 0000073290 2023-05-31 0000073290 BMRA:BuildingInMexicaliMexicoMember 2026-08-31 2026-08-31 0000073290 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2026-09-24 2026-09-24 0000073290 us-gaap:SubsequentEventMember BMRA:ConsultingAgreementMember 2026-09-24 2026-09-24 iso4217:USD shares iso4217:USD shares pure utr:sqft BMRA:Segment false --05-31 Q1 2027 0000073290

10-Q true 2026-08-31 false 001-37863 BIOMERICA, INC. DE 95-2645573 17571 Von Karman Avenue Irvine CA 92614 (949) 645-2111 Common Stock, par value $0.08 per share BMRA NASDAQ Yes Yes Non-accelerated Filer true false false 4598968

2733000

1308000

897000

785000

1634000

1707000

145000

216000

5409000

4016000

68000

78000

1809000

1873000

500000

204000

209000

81000

83000

8071000

6759000

1498000

1171000

500000

552000

492000

47000

83000

240000

235000

2837000

2481000

1586000

1648000

4423000

4129000

0.08

571429

4428571

0.08

300000000

25000000

4598968

3195263

368000

255000

61567000

59426000

-112000

-108000

-58175000

-56943000

3648000

2630000

8071000

6759000

1265000

1380000

1162000

956000

103000

424000

1124000

1330000

206000

212000

1330000

1542000

-1227000

-1118000

1000

1123000

1000

1123000

-1226000

5000

6000

3000

-1232000

2000

-0.37

0.00

-0.37

0.00

3295939

2638699

3295939

2638699

-1232000

2000

-4000

2000

-1236000

4000

3195263

255000

59426000

-108000

-56943000

2630000

-4000

1393705

112000

2119000

2231000

-111000

10000

1000

133000

134000

-1232000

4598968

368000

61567000

-112000

-58175000

3648000

2546216

203000

57175000

-105000

-53168000

4105000

2546216

203000

57175000

-105000

-53168000

4105000

3000

258569

21000

891000

912000

10625

1000

132000

133000

2000

2815410

225000

58198000

-102000

-53166000

5155000

2815410

225000

58198000

-102000

-53166000

5155000

-1232000

2000

15000

20000

3000

38000

-24000

7000

134000

133000

64000

82000

115000

512000

-97000

-10000

-71000

-87000

-2000

-5000

216000

10000

60000

-63000

-36000

-1000

-57000

-86000

-802000

-268000

2231000

939000

19000

2231000

920000

-4000

2000

1425000

654000

1308000

2399000

2733000

3053000

6000

3000

111000 8000 7000 7000

NOTE 1: BASIS OF PRESENTATION Biomerica, Inc. (“Biomerica,” “us,” “we,” “our,” or the “Company”) and its subsidiaries (which includes wholly-owned subsidiaries, Biomerica de Mexico and BioEurope GmbH) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (physicians’ offices and over-the-counter through drugstores and online) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. Our diagnostic test products utilize immunoassay technology to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of various diseases, food intolerances and other medical complications, and to measure the level of specific hormones, antibodies, antigens, or other substances, which may exist in the human body in extremely small concentrations. Our other existing products are primarily focused on gastrointestinal diseases, food intolerances, and certain esoteric tests. Our products are designed to enhance the health and well-being of people, while reducing total healthcare costs. We also provide contract development and manufacturing services to third parties that utilize the technology underlying our products. Our primary focus is the research, development, commercialization and, in certain cases, regulatory approval, of patented, diagnostic-guided therapy (“DGT”) products to treat gastrointestinal diseases, such as irritable bowel syndrome (“IBS”), and other inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread, common, and address very large markets. Our inFoods® IBS product uses a simple blood sample and is designed to identify patient-specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea, and constipation. Instead of broad and difficult to manage dietary restrictions, the inFoods® IBS product works by identifying specific foods that may be causing an abnormally high immune response in the patient, which in turn can lead to abdominal pain and cramping, bloating, diarrhea, and constipation. A food identified as positive, which is causing an abnormal immune response in the patient, is simply removed from the diet to help alleviate IBS symptoms. Our existing medical diagnostic products are sold worldwide primarily in two markets: (i) clinical laboratories and (ii) point-of-care (physicians’ offices and over-the-counter). Most of our products carry Conformité Européenne (“CE”) marking and/or are registered with regulatory agencies in various countries for diagnostic use. In addition, some products are cleared for sale in the U.S. by the U.S. Food and Drug Administration (“FDA”). The unaudited condensed consolidated financial statements herein have been prepared by management pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The accompanying unaudited condensed consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the latest fiscal year ended May 31, 2026. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the three months ended August 31, 2026 are not necessarily indicative of the results that may be expected for the fiscal year ending May 31, 2027. For further information, refer to the audited consolidated financial statements and notes thereto for the fiscal year ended May 31, 2026 included in our Annual Report on Form 10-K filed with the SEC on August 31, 2026, as amended on our Annual Report on Form 10-K/A, filed with the SEC on September 28, 2026. Management has evaluated all subsequent events and transactions through the date of filing this report.

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES PRINCIPLES OF CONSOLIDATION The condensed consolidated financial statements include the accounts of Biomerica, Inc. and its wholly owned subsidiaries, BioEurope GmbH and Biomerica de Mexico. All significant intercompany accounts and transactions have been eliminated in consolidation. ACCOUNTING ESTIMATES The preparation of our consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as the disclosure of contingent assets and liabilities as of the date of the financial statements. Such estimates and assumptions affect the reported amounts of revenues and expenses during the reporting period. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances. We believe our estimates and assumptions are reasonable under the current conditions; however, actual results may differ from these estimates under different future conditions. We believe that the estimates and assumptions that are most important to the portrayal of our financial condition and results of operations, in that they require subjective or complex judgments, form the basis for the accounting policies deemed to be most critical to us. These relate to revenue recognition, provision for expected credit losses on accounts receivable, inventory overhead application, inventory reserves, and share-based compensation. We believe estimates and assumptions related to these critical accounting estimates are appropriate under the circumstances; however, should future events or occurrences result in unanticipated consequences, there could be a material impact on our future financial condition or results of operations. We suggest that our significant accounting policies be read in conjunction with the Management’s Discussion and Analysis of Financial Condition and Results of Operations of this Quarterly Report on Form 10-Q. MARKETS AND METHODS OF DISTRIBUTION The majority of our revenues come from the sale of products we manufacture in the United States and Mexico, with certain raw materials sourced from the United States, Asia, and other regions. Our diagnostic business serves a diverse customer base that includes both domestic and international distributors, as well as hospitals, clinical laboratories, medical research institutions, pharmaceutical companies, drugstores, wholesalers, physicians’ offices, and e-commerce customers. A significant portion of our revenues are derived from international sales. We employ a Director of International Sales, based in Germany, who has over 25 years of experience in diagnostics and life sciences. This individual’s international business experience and multilingual capabilities have facilitated strong relationships across Europe, Eastern Europe, the Middle East, Latin America, Canada, and the United States. We are also pursuing new opportunities through the addition of distributors and product lines in these regions. We market our diagnostic products through distributors, advertising in medical and trade journals, trade show exhibitions, direct mailings, and through an internal sales team. The two primary markets we target are clinical laboratories and patient point-of-care testing. LIQUIDITY, CAPITAL RESOURCES, AND GOING CONCERN We have incurred net losses and negative cash flows from operations and have an accumulated deficit of approximately $58,175,000 as of August 31, 2026. As of August 31, 2026, we had cash and cash equivalents of approximately $2,733,000 and working capital of approximately $2,572,000. As of May 31, 2026, we had cash and cash equivalents of approximately $1,308,000 and working capital of approximately $1,535,000. Based on our current operating plan, we believe that our existing cash and cash equivalents will be insufficient to fund our operations and meet our obligations for the next twelve months from the issuance date of these financial statements. On September 28, 2023, we filed a “shelf” registration statement on Form S-3 with the SEC (the “Shelf Registration Statement”), which was declared effective on September 29, 2023, to replace the expiring “shelf” registration statement on Form S-3 that was filed on July 21, 2020, as amended on September 20, 2020, allowing us to issue up to $20,000,000 in shares of our common stock. Under the Shelf Registration Statement, shares of our common stock may be sold from time to time for up to three years from its initial effective date. The Shelf Registration Statement reached its third anniversary on September 29, 2026 and has been replaced by a new shelf registration statement, as described below. On May 10, 2024, we filed a prospectus supplement to the Shelf Registration Statement with the SEC to facilitate the sale of up to $5,500,000 in common stock through at-the-market (“ATM”) offerings, as defined in Rule 415 under the Securities Act (the “2024 ATM Offering”). As part of this transaction, we incurred $81,000 in deferred offering costs during the year ended May 31, 2024, all of which had been charged against additional paid-in capital as of May 31, 2026. On September 24, 2026, subsequent to quarter-end, we filed a replacement shelf registration statement on Form S-3 with the SEC registering up to $<span id="xdx_90A_ecustom--ReplacementShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_c20260924__20260924__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKB9z2bo2O31" title="Aggregate offering price">250,000,000 of common stock, preferred stock, debt securities and warrants, including unsold common stock carried forward from our prior shelf registration statement pursuant to Rule 415(a)(6) under the Securities Act. The replacement shelf registration statement was declared effective by the SEC on October 7, 2026. The Shelf Registration Statement does not represent committed financing. Our ability to raise capital under it is subject to applicable Form S-3 eligibility requirements and offering limitations, including General Instruction I.B.6, and market conditions. During the three months ended August 31, 2026, we did not sell any shares of common stock pursuant to the 2024 ATM Offering. On August 26, 2026, we completed a private placement pursuant to a Securities Purchase Agreement (“SPA”) with accredited investors and issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260601__20260831__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zxSI8ALUxQQd" title="Stock issued during period, shares, new issues">1,393,705 shares of our common stock at $1.60 per share, resulting in gross proceeds of approximately $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20260601__20260831__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zGqzkTfkpDf3" title="Sale of stock, consideration received on transaction">2,231,000 and net proceeds after legal fees and other offering costs of approximately $2,120,000. Offering costs totaled approximately $111,000 and were accrued and unpaid as of August 31, 2026. We intend to use the net proceeds of the August 2026 private placement and any future sales under the 2024 ATM Offering for general corporate purposes, including, but not limited to, sales and marketing activities, clinical studies and product development, acquisitions of assets, businesses, companies, or securities, capital expenditures, and working capital needs. Our ability to meet our obligations and continue as a going concern is influenced by several factors, including: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our need and ability to generate additional revenue from international opportunities and sales within the United States of existing products, and from our new product launches;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our need and ability to access the capital and debt markets to meet current obligations and fund operations;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our capacity to manage operating expenses and maintain or increase gross margins;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our ability to retain key employees and maintain critical operations; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Certain SEC regulations that limit the amount of capital we can raise through issuance of our equity.</td></tr> </table> These factors raise substantial doubt about our ability to continue as a going concern within twelve months following the issuance date of these financial statements. Our future viability depends on the successful execution of our strategic plans, securing additional near-term financing, and achieving profitable operations. Management has evaluated our cash flow requirements for the twelve months following the issuance date of these financial statements. Based on this evaluation, our existing cash and cash equivalents are insufficient to fund our operations and meet our obligations during that period. To address our capital needs and sustain operations through the next year and beyond, we are actively pursuing strategies to increase sales, reduce expenses, sell non-core assets, seek additional financing through debt or equity issuance, and seek other strategic alternatives. If we are unable to generate sufficient cash flows from operations or obtain additional financing, we may be required to delay or reduce certain operating activities and expenditures. While we are committed to these plans, there can be no assurance that these efforts will be successful or sufficient to meet our near-term capital requirements, or to enable the Company to continue as a going concern. Our condensed consolidated financial statements as of August 31, 2026, were prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. Our continuance as a going concern is dependent upon our ability to obtain additional operating capital and achieve revenues and attain profitability. We intend to finance our future development activities and our working capital needs primarily from the sale of equity and debt securities, combined with additional funding from other sources. However, there can be no assurance that future funding will be available to us when needed on terms that are acceptable to us, or at all or that we will be successful in these endeavors. CONCENTRATION OF CREDIT RISK We maintain cash balances at certain financial institutions in excess of amounts insured by federal agencies. From time to time, we have uninsured balances. We do not believe we are exposed to any significant credit risk. We provide credit in the normal course of business to customers throughout the United States and in foreign markets. We perform ongoing credit evaluations of our customers and require accelerated prepayment in certain circumstances. Consolidated net sales were approximately $1,265,000 and $1,380,000 for the three months ended August 31, 2026, and 2025, respectively. For the three months ended August 31, 2026 and 2025, we had one key customer located in Asia, which accounted for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260601__20260831__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneKeyCustomersMember__srt--StatementGeographicalAxis__srt--AsiaMember_zY154y2oY0v8" title="Concentration risk, percentage">36% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250601__20250831__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneKeyCustomersMember__srt--StatementGeographicalAxis__srt--AsiaMember_zD5wPWya1cZk" title="Concentration risk, percentage">48% of net consolidated sales, respectively. As of August 31, 2026 and May 31, 2026, total gross receivables were approximately $938,000 and $823,000, respectively. As of those dates, we had one and three key distributors, respectively, located in Asia and North America, which accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260601__20260831__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeKeyCustomersMember_zMDCxGnVQa28">48% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250601__20260531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeKeyCustomersMember_zFWwHh1AoWba">59% of gross accounts receivable, respectively. For the three months ended August 31, 2026, we had one key vendor that accounted for <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250601__20250831__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneKeyVendorMember_z6lJ2f78Inq9" title="Concentration risk, percentage">24% of purchases of raw materials. For the three months ended August 31, 2025, no vendor accounted for <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250601__20250831__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneVendorMember_zOx6qXOxYaDa" title="Concentration risk, percentage">10% or more of total raw material purchases. As of August 31, 2026 and May 31, 2026, one vendor and two vendors accounted for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260601__20260831__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsPayablesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneVendorMember_zWV3l889euo7" title="Concentration risk, percentage">20% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250601__20260531__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsPayablesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoVendorsMember_z5Dvwqr9qxf7" title="Concentration risk, percentage">23%, respectively, of accounts payable. CASH AND CASH EQUIVALENTS Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months. ACCOUNTS RECEIVABLE We extend unsecured credit to customers as part of our standard business practices. International customers are typically required to prepay until a credit history has been established, at which point credit levels are determined based on various criteria. Initial credit limits for distributors are approved by designated officers or managers, while any increases require authorization from upper-level management. We account for expected credit losses on accounts receivable under Accounting Standards Codification (“ASC”) 326, Financial Instruments—Credit Losses, using the current expected credit loss (“CECL”) model. Effective June 1, 2026, we adopted Accounting Standards Update (“ASU”) 2025-05, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, on a prospective basis and elected the practical expedient for qualifying current accounts receivable arising from transactions accounted for under ASC 606. Under this practical expedient, we assume that current conditions as of the balance sheet date remain unchanged over the remaining life of these receivables. We estimate expected credit losses based on historical credit loss experience adjusted for current conditions, including aging and collection trends, customer and portfolio characteristics, and customer-specific credit risks. In developing our expected credit loss estimate, we evaluate receivables collectively when they share similar risk characteristics and individually when they do not. Accounts receivable are presented net of an allowance for expected credit losses. Account balances are written off against the allowance for expected credit losses when deemed uncollectible. Occasionally, certain long-standing customers that routinely place large orders may have receivable balances that are significant relative to total gross receivables. Management closely monitors collection of these balances and may require payment of existing invoices before shipping new sales orders. The allowance for expected credit losses was approximately $41,000 and $38,000 as of August 31, 2026 and May 31, 2026, respectively. PREPAID EXPENSES AND OTHER CURRENT ASSETS We occasionally prepay for items such as inventory, insurance, and other items. These items are reported as prepaid expenses and other current assets, until either the inventory is physically received, or the insurance and other items are expensed. As of August 31, 2026 and May 31, 2026, prepaids were approximately $145,000 and $216,000, respectively, composed of prepayments to insurance and various other suppliers. INVENTORIES, NET We value inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out method) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. In evaluating inventory, management considers quantities on hand, physical condition, and technical functionality, as these characteristics may be impacted by anticipated customer demand for existing products and new product introductions. The inventory reserve is adjusted based on this evaluation, with a corresponding provision recognized in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs, and wasted materials are recognized as current period charges. The allocation of fixed production overhead is based on the normal capacity of the production facilities. Net inventories are comprised of approximately the following: SCHEDULE OF NET INVENTORIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-right: 1in; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260831_z2fx8qfBzt27" style="border-bottom: Black 1pt solid; text-align: center">August 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260531_zgI0dBRjMFi9" style="border-bottom: Black 1pt solid; text-align: center">May 31, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maIGzLcj_zMGnQ0hcZ7O4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,089,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,054,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--InventoryWorkInProcess_iI_maIGzLcj_zXfUdE8gVkp5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">648,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">868,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_maIGzLcj_z2Ix9qZAJPgj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Finished products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">267,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">179,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryGross_iTI_mtIGzLcj_maINzi6L_z27Dezufyfw2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total gross inventory</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,004,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,101,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryValuationReserves_iNI_di_msINzi6L_zaXXt6fm65ka" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Inventory reserves</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(370,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(394,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--InventoryNet_iTI_mtINzi6L_ztGth2eGIei2" style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal"> <td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left">Net inventory</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right">1,634,000</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right">1,707,000</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td></tr> </table> Reserves for inventory obsolescence are recognized as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory. As of August 31, 2026, and May 31, 2026, inventory reserves were approximately $370,000 and $394,000, respectively. PROPERTY AND EQUIPMENT, NET Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired, or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income. Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense related to property and equipment was approximately $<span id="xdx_90C_eus-gaap--DepreciationDepletionAndAmortization_c20260601__20260831__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zjWoaFqG6h87" title="Depreciation and amortization expense">10,000 and $<span id="xdx_901_eus-gaap--DepreciationDepletionAndAmortization_c20250601__20250831__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zTykqN8yvFb7" title="Depreciation and amortization expense">15,000 for the three months ended August 31, 2026 and 2025, respectively. INTANGIBLE ASSETS, NET Intangible assets include trademarks, product rights, technology rights, and patents, and are accounted for in accordance with ASC 350, Intangibles—Goodwill and Other. Intangible assets with indefinite useful lives are not amortized but are tested annually for impairment, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Intangible assets with finite useful lives are amortized using the straight-line method over their estimated useful lives, not to exceed <span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260831__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--MarketingAndDistributionRightsMember_zuhh2lfcWFyf" title="Intangible assets estimated useful lives">18 years for marketing and distribution rights and <span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260831__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedTechnologyRightsMember_zSbdRrGrOyaa" title="Intangible assets estimated useful lives">10 years for purchased technology rights. Patents are amortized over their respective estimated useful lives, which average approximately <span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260831__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zjn8NlJebbD5" title="Intangible assets estimated useful lives">15 years. Amortization expense was approximately $5,000 for the three months ended August 31, 2026, and 2025, respectively. Amortizing intangible assets are tested for impairment if management determines that events or changes in circumstances indicate that the asset might be impaired. We assess the recoverability of finite-lived intangible assets under ASC 360 by determining whether the carrying value of the applicable asset group can be recovered through projected undiscounted future cash flows. If the carrying amount is not recoverable, an impairment loss is recognized for the amount by which the carrying amount exceeds fair value. During the three months ended August 31, 2026 and 2025, no impairment charges were recognized. INVESTMENTS We have made investments in a privately held Polish distributor, which is primarily engaged in distributing medical products and devices, including the distribution of the products sold by us. We invested approximately $165,000 into the Polish distributor and own approximately <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20260831__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PolishDistributorMember_zYhCAli5W7d3" title="Equity method investment, ownership percentage">6% of the Polish distributor. Equity holdings in nonmarketable unconsolidated entities in which we are not able to exercise significant influence are accounted for under the measurement alternative in ASC 321 at our initial cost, minus any impairment, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar securities of the same issuer. Dividends received are recognized in dividend, interest, and other income. We assess our equity holdings for impairment whenever events or changes in circumstances indicate that the carrying value of an equity holding may not be recoverable. Management reviewed the underlying net assets of our equity holding as of August 31, 2026 and determined that our proportionate economic interest in the entity indicates that the equity holding was not impaired. There were no observable price changes in orderly transactions for identical or similar security of the same issuer during the three months ended August 31, 2026 and August 31, 2025. On May 29, 2026, we entered into a SPA to sell our entire investment in Diagnosis S.A. for an aggregate purchase price of $500,000 in a related-party transaction involving our Chief Executive Officer and other purchasers. During the year ended May 31, 2026, we increased the carrying amount of the investment from approximately $165,000 to $500,000 and recognized an unrealized holding gain of approximately $335,000 based on the executed SPA. Pending completion of the applicable share transfers and required procedures under Polish law, we received $500,000 in cash and issued a secured promissory term note to our Chief Executive Officer. The note bears interest at <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20260531__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PolishDistributorMember_zaQctoTQ4uLb" title="Equity method investment, ownership percentage">8% per annum, matures on May 29, 2027, and is secured by our rights and interests in the Diagnosis S.A. shares. As of August 31, 2026, the share transfer had not been completed, and we continued to recognize the investment and the related note payable. The share transfer remains in process, subject to completion of the applicable procedures required under Polish law. As of August 31, 2026, the carrying amount of our investment in Diagnosis S.A. was approximately $500,000. Cumulative upward adjustments were approximately $335,000, and no cumulative impairment or downward adjustments had been recognized as of August 31, 2026. SHARE-BASED COMPENSATION We follow the guidance of ASC 718, Share-based Compensation, which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments. Restricted stock awards are measured at grant-date fair value based on the fair value of our common stock. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model with assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. We have not paid dividends historically and do not expect to pay them in the foreseeable future. Expected volatilities are based on weighted averages of the historical volatility of our common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term as historically we had limited exercise activity surrounding our options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. The grant date fair value of the award is recognized under the straight-line attribution method. The following summary presents the options granted, exercised, expired, cancelled and outstanding for the three months ended August 31, 2026: SUMMARY OF OPTIONS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-style: normal; font-weight: normal"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Option Shares</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal"> <td style="font-style: normal; width: 60%; font-weight: normal">Options Outstanding at May 31, 2026</td><td style="font-style: normal; width: 2%; font-weight: normal"> </td> <td style="font-style: normal; width: 1%; font-weight: normal; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260601__20260831_z63N54aW47va" style="font-style: normal; width: 16%; font-weight: normal; text-align: right" title="Option Shares, Option outstanding, beginning balance">454,384</td><td style="font-style: normal; width: 1%; font-weight: normal; text-align: left"> </td><td style="font-style: normal; width: 2%; font-weight: normal"> </td> <td style="font-style: normal; width: 1%; font-weight: normal; text-align: left">$</td><td style="font-style: normal; width: 16%; font-weight: normal; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260601__20260831_zHqxklH4qaBj" style="font-style: normal; font-weight: normal">16.88</td><td style="font-style: normal; width: 1%; font-weight: normal; text-align: left"> </td></tr> <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal"> <td style="font-style: normal; text-align: left; padding-bottom: 1pt; font-weight: normal">Canceled or expired</td><td style="font-style: normal; padding-bottom: 1pt; font-weight: normal"> </td> <td style="border-bottom: Black 1pt solid; font-style: normal; text-align: left; font-weight: normal"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20260601__20260831_zoUBzp6gm8z1" style="border-bottom: Black 1pt solid; font-style: normal; text-align: right; font-weight: normal" title="Option Shares, Cancelled or expired">(25,001</td><td style="font-style: normal; padding-bottom: 1pt; text-align: left; font-weight: normal">)</td><td style="font-style: normal; padding-bottom: 1pt; font-weight: normal"> </td> <td style="border-bottom: Black 1pt solid; font-style: normal; text-align: left; font-weight: normal"> </td><td style="border-bottom: Black 1pt solid; font-style: normal; text-align: right; font-weight: normal"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260601__20260831_zCWJK6zxWH7i" style="font-style: normal; font-weight: normal">10.64</td><td style="font-style: normal; padding-bottom: 1pt; text-align: left; font-weight: normal"> </td></tr> <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal"> <td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt">Options Outstanding at August 31, 2026</td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260601__20260831_zkpDHD3zOSDg" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Option Shares, Option outstanding, ending balance">429,383</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260601__20260831_zIG9T64fyGCd" style="font-style: normal; font-weight: normal">17.24</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td></tr> <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal"> <td style="font-style: normal; font-weight: normal; text-align: left; padding-bottom: 2.5pt">Options vested and exercisable at August 31, 2026</td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20260601__20260831_z6GN5KW1Tkal" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Option Shares, Options vested and exercisable, ending balance">284,394</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260601__20260831_z9QYYCBoqpm9" style="font-style: normal; font-weight: normal">24.14</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td></tr> </table> During the three months ended August 31, 2026, we recognized approximately $40,000 of share-based compensation expense related to stock options, compared to approximately $74,000 for the three months ended August 31, 2025. During the three months ended August 31, 2026, we also issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20260601__20260831__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zGExJwAtyZYb" title="Shares issued for consulting services">10,000 shares of common stock pursuant to a consulting agreement. The shares had an aggregate fair value of approximately $<span id="xdx_908_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_c20260601__20260831__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zKz3hsLywZZ4" title="Common stock issued for consultant services">21,000, which was recognized as a share-based compensation expense. <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20250601__20250831__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zzJFTZWReXjf" title="Shares issued for consulting services">No shares were issued for consulting services during the three months ended August 31, 2025. <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zNByCVjEWPg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following summary presents the restricted stock awards granted, vested, forfeited and outstanding for the three months ended August 31, 2026: SCHEDULE OF RSUs ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-style: normal; font-weight: normal"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Restricted Stock Awards</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: normal; width: 60%; font-weight: normal; text-align: left">Unvested Restricted Stock Awards at May 31, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20260601__20260831_zMV6QPYrWCAk" style="width: 16%; text-align: right" title="Restricted Stock Awards, Outstanding, beginning balance">168,437</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue_iS_c20260601__20260831_zfBf0szK1XYe" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding, beginning balance">2.57</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: normal; font-weight: normal">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20260601__20260831_z3hZT0evmah8" style="text-align: right" title="Restricted Stock Awards, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue_c20260601__20260831_z5b54mdBedn5" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: normal; padding-bottom: 1pt; font-weight: normal">Vested</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_pid_c20260601__20260831_zc8cgKwxHNwk" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted Stock Awards, Vested">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageVestDateFairValue_c20260601__20260831_zk6M2TmPdxij" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Vested">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal"> <td style="font-style: normal; font-weight: normal; text-align: left; padding-bottom: 2.5pt">Unvested Restricted Stock Awards at August 31, 2026</td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20260601__20260831_zkA3KUCsrsn6" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Stock Awards, Outstanding, ending balance">168,437</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue_iE_c20260601__20260831_zI1RCAF7R95c" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding, ending balance">2.57</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td></tr> </table> During the three months ended August 31, 2026, we recognized approximately $73,000 of share-based compensation expense related to restricted stock awards, compared to approximately $59,000 for the three months ended August 31, 2025. REVENUE RECOGNITION We have various contracts with customers, and these contracts specify the recognition of revenue based on the nature of the transaction. Revenues from product sales are recognized at the time the product is shipped, customarily Freight on Board (“FOB”) shipping point, which is when control of the goods transfers and title passes to the customer. This applies to clinical lab products sold to domestic and international distributors, including hospitals, clinical laboratories, medical research institutions, medical schools, and pharmaceutical companies. Over-the-counter (“OTC”) products are sold directly to e-commerce customers and distributors, while physicians’ office products are sold to physicians and distributors. We generally do not allow returns except in cases of defective merchandise, and therefore, do not establish an allowance for returns. Additionally, we have contracts with customers that provide purchase discounts contingent on achieving specified sales volumes. These contracts are regularly evaluated, and we do not anticipate granting any discounts through the end of the contract period. For diagnostic testing services sold directly to patients or physician offices that require processing by a third-party CLIA-certified lab, we recognize revenue once the lab has completed the test results. For services related to contract manufacturing, revenue is recognized when the service has been performed. For certain contracts, revenue is recognized over time as services are performed, measured based on progress toward completion. As of August 31, 2026, we had approximately $47,000 in advances from domestic customers, which are prepayments on orders for future shipments. Disaggregation of revenue: The following is a breakdown of revenues according to markets to which the products are sold: SCHEDULE OF DISAGGREGATION REVENUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-right: 0.25in; margin-left: 0.25in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260601__20260831_zGzofferTau4" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250601__20250831_zv2dbjJ6QLRb" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ClinicalLabMember_zJIQWdZ9QdQf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Clinical lab</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">775,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,024,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OverTheCounteMember_zVl3aZibgGsc" style="vertical-align: bottom; background-color: White"> <td>Over-the-counter</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">291,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ContractManufacturingMember_zFH6kW9zVUdg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contract manufacturing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">197,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">192,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PhysiciansOfficeMember_zgbJXOQtTCW8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Physician’s office</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_ztJQage1a5y" style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal"> <td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal">Total</td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right">1,265,000</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right">1,380,000</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td></tr> </table> See Note 4 for additional information regarding geographic revenue concentrations. SHIPPING AND HANDLING FEES We include shipping and handling fees billed to customers in net sales. RESEARCH AND DEVELOPMENT Research and development costs are expensed as incurred. We recognized approximately $206,000 and $212,000 of research and development costs during the three months ended August 31, 2026 and August 31, 2025, respectively. INCOME TAXES For the three months ended August 31, 2026 and 2025, we recognized income tax expense of approximately $6,000 and $3,000, respectively. These expenses consisted of state minimum taxes and miscellaneous foreign taxes. During the three months ended August 31, 2026, we had a net operating loss (“NOL”) that generated deferred tax assets for NOL carryforwards. Deferred income tax assets and liabilities are recognized for temporary differences between the financial statements and income tax carrying values using enacted tax rates expected to apply when such differences are expected to reverse. Due to uncertainties surrounding our ability to generate future taxable income and consequently realize such deferred income tax assets, we have determined that it is more likely than not that these deferred tax assets will not be realized. Accordingly, we have maintained a full valuation allowance against the Company’s net deferred tax assets as of August 31, 2026. Our policy is to recognize any interest and penalties related to unrecognized tax benefits as a component of income tax expense. As of August 31, 2026, we had no accrued interest or penalties related to uncertain tax positions. ADVERTISING COSTS We report the cost of advertising as an expense in the period in which those costs are incurred. For the three months ended August 31, 2026, and August 31, 2025, advertising costs were approximately $8,000 and $9,000, respectively. FOREIGN CURRENCY TRANSLATION Biomerica de Mexico, our subsidiary located in Mexico, operates primarily using the Mexican peso. BioEurope GmbH, our subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring in euros. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the period, and revenues and costs are translated using average exchange rates for the period. The resulting translation adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no foreign currency transactions that are included in the condensed consolidated statements of operations and comprehensive loss for the three months ended August 31, 2026 and August 31, 2025. RIGHT-OF-USE ASSETS AND LEASE LIABILITIES We account for our leases in accordance with ASC 842, Leases. We lease office space and copy machines, all of which are operating leases. Most leases include the option to renew and the exercise of the renewal options is at our sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise. Our leases do not include the options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited by the expected lease term. NET (LOSS) INCOME PER SHARE Basic net (loss) income per share is computed as net (loss) income divided by the weighted-average number of common shares outstanding for the period. Diluted (loss) income per share reflects the potential dilution that could occur from common shares issuable upon the vesting of restricted stock units and from the exercise of stock options, and warrants using the treasury stock method, and from convertible securities using the if-converted method. The following potentially dilutive securities were excluded from the calculation of diluted (loss) income per share because their effect would have been anti-dilutive: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Stock options of 429,383 and 413,146 as of August 31, 2026 and 2025, respectively; and</td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Restricted stock units of 168,437 and 96,875 as of August 31, 2026 and 2025, respectively</td> </tr> </table> SEGMENT REPORTING We define our segments on the basis in which internally reported financial information is reviewed by the Chief Operating Decision Maker (the “CODM”) to analyze financial performance, make decisions, and allocate resources. We manage our operations as a 1single operating and reportable segment, which focuses on the development, manufacture, marketing, and sale of diagnostic products. As all material financial information is included in the consolidated results we have identified one reportable segment. The CODM uses net (loss) income and cash flow information to evaluate performance, including detailed cost information as part of the budget and forecasting process and considers budget-to-actual variances on a regular basis when making decisions about the allocation of operating and capital resources. We measure segment profit or loss in net (loss) income as reported in the consolidated financial statements. The accounting policies used in the segment reporting are the same as those described in the summary of significant accounting policies. Our CODM is the Chief Executive Officer. RECENT ACCOUNTING PRONOUNCEMENTS In November 2024, the FASB issued ASU 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40)”. The ASU includes enhanced disclosure requirements, which mandate enhanced transparency in financial statements by requiring detailed disclosures of specific expenses like inventory purchases, employee compensation, depreciation, and intangible asset amortization. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures. In July 2025, the FASB issued Update ASU 2025-05, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets”. This ASU provides targeted amendments to clarify the measurement of expected credit losses for accounts receivable and contract assets and introduces a practical expedient and related accounting policy election for certain entities. The amendments are effective for annual reporting periods beginning after December 15, 2025, including interim reporting periods within those annual reporting periods, with early adoption permitted. We adopted ASU 2025-05 effective June 1, 2026. The adoption did not have a material impact on our consolidated financial statements or related disclosures. In December 2025, the FASB issued Update ASU 2025-11, “Interim Reporting (Topic 270): Narrow-Scope Improvements”. This ASU clarifies and improves existing interim reporting guidance by consolidating disclosure requirements within Topic 270 and introducing a disclosure principle requiring entities to disclose events and changes occurring after the most recent annual reporting period that are expected to have a material effect on the entity’s financial condition or results of operations. The ASU does not introduce significant changes to recognition or measurement guidance. The amendments in this Update are effective for interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures.

PRINCIPLES OF CONSOLIDATION The condensed consolidated financial statements include the accounts of Biomerica, Inc. and its wholly owned subsidiaries, BioEurope GmbH and Biomerica de Mexico. All significant intercompany accounts and transactions have been eliminated in consolidation.

ACCOUNTING ESTIMATES The preparation of our consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as the disclosure of contingent assets and liabilities as of the date of the financial statements. Such estimates and assumptions affect the reported amounts of revenues and expenses during the reporting period. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances. We believe our estimates and assumptions are reasonable under the current conditions; however, actual results may differ from these estimates under different future conditions. We believe that the estimates and assumptions that are most important to the portrayal of our financial condition and results of operations, in that they require subjective or complex judgments, form the basis for the accounting policies deemed to be most critical to us. These relate to revenue recognition, provision for expected credit losses on accounts receivable, inventory overhead application, inventory reserves, and share-based compensation. We believe estimates and assumptions related to these critical accounting estimates are appropriate under the circumstances; however, should future events or occurrences result in unanticipated consequences, there could be a material impact on our future financial condition or results of operations. We suggest that our significant accounting policies be read in conjunction with the Management’s Discussion and Analysis of Financial Condition and Results of Operations of this Quarterly Report on Form 10-Q.

MARKETS AND METHODS OF DISTRIBUTION The majority of our revenues come from the sale of products we manufacture in the United States and Mexico, with certain raw materials sourced from the United States, Asia, and other regions. Our diagnostic business serves a diverse customer base that includes both domestic and international distributors, as well as hospitals, clinical laboratories, medical research institutions, pharmaceutical companies, drugstores, wholesalers, physicians’ offices, and e-commerce customers. A significant portion of our revenues are derived from international sales. We employ a Director of International Sales, based in Germany, who has over 25 years of experience in diagnostics and life sciences. This individual’s international business experience and multilingual capabilities have facilitated strong relationships across Europe, Eastern Europe, the Middle East, Latin America, Canada, and the United States. We are also pursuing new opportunities through the addition of distributors and product lines in these regions. We market our diagnostic products through distributors, advertising in medical and trade journals, trade show exhibitions, direct mailings, and through an internal sales team. The two primary markets we target are clinical laboratories and patient point-of-care testing. LIQUIDITY, CAPITAL RESOURCES, AND GOING CONCERN We have incurred net losses and negative cash flows from operations and have an accumulated deficit of approximately $58,175,000 as of August 31, 2026. As of August 31, 2026, we had cash and cash equivalents of approximately $2,733,000 and working capital of approximately $2,572,000. As of May 31, 2026, we had cash and cash equivalents of approximately $1,308,000 and working capital of approximately $1,535,000. Based on our current operating plan, we believe that our existing cash and cash equivalents will be insufficient to fund our operations and meet our obligations for the next twelve months from the issuance date of these financial statements. On September 28, 2023, we filed a “shelf” registration statement on Form S-3 with the SEC (the “Shelf Registration Statement”), which was declared effective on September 29, 2023, to replace the expiring “shelf” registration statement on Form S-3 that was filed on July 21, 2020, as amended on September 20, 2020, allowing us to issue up to $20,000,000 in shares of our common stock. Under the Shelf Registration Statement, shares of our common stock may be sold from time to time for up to three years from its initial effective date. The Shelf Registration Statement reached its third anniversary on September 29, 2026 and has been replaced by a new shelf registration statement, as described below. On May 10, 2024, we filed a prospectus supplement to the Shelf Registration Statement with the SEC to facilitate the sale of up to $5,500,000 in common stock through at-the-market (“ATM”) offerings, as defined in Rule 415 under the Securities Act (the “2024 ATM Offering”). As part of this transaction, we incurred $81,000 in deferred offering costs during the year ended May 31, 2024, all of which had been charged against additional paid-in capital as of May 31, 2026. On September 24, 2026, subsequent to quarter-end, we filed a replacement shelf registration statement on Form S-3 with the SEC registering up to $<span id="xdx_90A_ecustom--ReplacementShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_c20260924__20260924__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKB9z2bo2O31" title="Aggregate offering price">250,000,000 of common stock, preferred stock, debt securities and warrants, including unsold common stock carried forward from our prior shelf registration statement pursuant to Rule 415(a)(6) under the Securities Act. The replacement shelf registration statement was declared effective by the SEC on October 7, 2026. The Shelf Registration Statement does not represent committed financing. Our ability to raise capital under it is subject to applicable Form S-3 eligibility requirements and offering limitations, including General Instruction I.B.6, and market conditions. During the three months ended August 31, 2026, we did not sell any shares of common stock pursuant to the 2024 ATM Offering. On August 26, 2026, we completed a private placement pursuant to a Securities Purchase Agreement (“SPA”) with accredited investors and issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260601__20260831__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zxSI8ALUxQQd" title="Stock issued during period, shares, new issues">1,393,705 shares of our common stock at $1.60 per share, resulting in gross proceeds of approximately $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20260601__20260831__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zGqzkTfkpDf3" title="Sale of stock, consideration received on transaction">2,231,000 and net proceeds after legal fees and other offering costs of approximately $2,120,000. Offering costs totaled approximately $111,000 and were accrued and unpaid as of August 31, 2026. We intend to use the net proceeds of the August 2026 private placement and any future sales under the 2024 ATM Offering for general corporate purposes, including, but not limited to, sales and marketing activities, clinical studies and product development, acquisitions of assets, businesses, companies, or securities, capital expenditures, and working capital needs. Our ability to meet our obligations and continue as a going concern is influenced by several factors, including: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our need and ability to generate additional revenue from international opportunities and sales within the United States of existing products, and from our new product launches;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our need and ability to access the capital and debt markets to meet current obligations and fund operations;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our capacity to manage operating expenses and maintain or increase gross margins;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our ability to retain key employees and maintain critical operations; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Certain SEC regulations that limit the amount of capital we can raise through issuance of our equity.</td></tr> </table> These factors raise substantial doubt about our ability to continue as a going concern within twelve months following the issuance date of these financial statements. Our future viability depends on the successful execution of our strategic plans, securing additional near-term financing, and achieving profitable operations. Management has evaluated our cash flow requirements for the twelve months following the issuance date of these financial statements. Based on this evaluation, our existing cash and cash equivalents are insufficient to fund our operations and meet our obligations during that period. To address our capital needs and sustain operations through the next year and beyond, we are actively pursuing strategies to increase sales, reduce expenses, sell non-core assets, seek additional financing through debt or equity issuance, and seek other strategic alternatives. If we are unable to generate sufficient cash flows from operations or obtain additional financing, we may be required to delay or reduce certain operating activities and expenditures. While we are committed to these plans, there can be no assurance that these efforts will be successful or sufficient to meet our near-term capital requirements, or to enable the Company to continue as a going concern. Our condensed consolidated financial statements as of August 31, 2026, were prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. Our continuance as a going concern is dependent upon our ability to obtain additional operating capital and achieve revenues and attain profitability. We intend to finance our future development activities and our working capital needs primarily from the sale of equity and debt securities, combined with additional funding from other sources. However, there can be no assurance that future funding will be available to us when needed on terms that are acceptable to us, or at all or that we will be successful in these endeavors.

-58175000

2733000

2572000

1308000

1535000 20000000 5500000

81000

250000000

1393705

1.60

2231000

2120000

111000

CONCENTRATION OF CREDIT RISK We maintain cash balances at certain financial institutions in excess of amounts insured by federal agencies. From time to time, we have uninsured balances. We do not believe we are exposed to any significant credit risk. We provide credit in the normal course of business to customers throughout the United States and in foreign markets. We perform ongoing credit evaluations of our customers and require accelerated prepayment in certain circumstances. Consolidated net sales were approximately $1,265,000 and $1,380,000 for the three months ended August 31, 2026, and 2025, respectively. For the three months ended August 31, 2026 and 2025, we had one key customer located in Asia, which accounted for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260601__20260831__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneKeyCustomersMember__srt--StatementGeographicalAxis__srt--AsiaMember_zY154y2oY0v8" title="Concentration risk, percentage">36% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250601__20250831__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneKeyCustomersMember__srt--StatementGeographicalAxis__srt--AsiaMember_zD5wPWya1cZk" title="Concentration risk, percentage">48% of net consolidated sales, respectively. As of August 31, 2026 and May 31, 2026, total gross receivables were approximately $938,000 and $823,000, respectively. As of those dates, we had one and three key distributors, respectively, located in Asia and North America, which accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260601__20260831__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeKeyCustomersMember_zMDCxGnVQa28">48% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250601__20260531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeKeyCustomersMember_zFWwHh1AoWba">59% of gross accounts receivable, respectively. For the three months ended August 31, 2026, we had one key vendor that accounted for <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250601__20250831__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneKeyVendorMember_z6lJ2f78Inq9" title="Concentration risk, percentage">24% of purchases of raw materials. For the three months ended August 31, 2025, no vendor accounted for <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250601__20250831__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneVendorMember_zOx6qXOxYaDa" title="Concentration risk, percentage">10% or more of total raw material purchases. As of August 31, 2026 and May 31, 2026, one vendor and two vendors accounted for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260601__20260831__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsPayablesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneVendorMember_zWV3l889euo7" title="Concentration risk, percentage">20% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250601__20260531__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsPayablesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoVendorsMember_z5Dvwqr9qxf7" title="Concentration risk, percentage">23%, respectively, of accounts payable.

1265000

1380000

0.36

0.48

938000

823000

0.48

0.59

0.24

0.10

0.20

0.23

CASH AND CASH EQUIVALENTS Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.

ACCOUNTS RECEIVABLE We extend unsecured credit to customers as part of our standard business practices. International customers are typically required to prepay until a credit history has been established, at which point credit levels are determined based on various criteria. Initial credit limits for distributors are approved by designated officers or managers, while any increases require authorization from upper-level management. We account for expected credit losses on accounts receivable under Accounting Standards Codification (“ASC”) 326, Financial Instruments—Credit Losses, using the current expected credit loss (“CECL”) model. Effective June 1, 2026, we adopted Accounting Standards Update (“ASU”) 2025-05, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, on a prospective basis and elected the practical expedient for qualifying current accounts receivable arising from transactions accounted for under ASC 606. Under this practical expedient, we assume that current conditions as of the balance sheet date remain unchanged over the remaining life of these receivables. We estimate expected credit losses based on historical credit loss experience adjusted for current conditions, including aging and collection trends, customer and portfolio characteristics, and customer-specific credit risks. In developing our expected credit loss estimate, we evaluate receivables collectively when they share similar risk characteristics and individually when they do not. Accounts receivable are presented net of an allowance for expected credit losses. Account balances are written off against the allowance for expected credit losses when deemed uncollectible. Occasionally, certain long-standing customers that routinely place large orders may have receivable balances that are significant relative to total gross receivables. Management closely monitors collection of these balances and may require payment of existing invoices before shipping new sales orders. The allowance for expected credit losses was approximately $41,000 and $38,000 as of August 31, 2026 and May 31, 2026, respectively.

41000

38000

PREPAID EXPENSES AND OTHER CURRENT ASSETS We occasionally prepay for items such as inventory, insurance, and other items. These items are reported as prepaid expenses and other current assets, until either the inventory is physically received, or the insurance and other items are expensed. As of August 31, 2026 and May 31, 2026, prepaids were approximately $145,000 and $216,000, respectively, composed of prepayments to insurance and various other suppliers.

145000

216000

INVENTORIES, NET We value inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out method) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. In evaluating inventory, management considers quantities on hand, physical condition, and technical functionality, as these characteristics may be impacted by anticipated customer demand for existing products and new product introductions. The inventory reserve is adjusted based on this evaluation, with a corresponding provision recognized in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs, and wasted materials are recognized as current period charges. The allocation of fixed production overhead is based on the normal capacity of the production facilities. Net inventories are comprised of approximately the following: SCHEDULE OF NET INVENTORIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-right: 1in; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260831_z2fx8qfBzt27" style="border-bottom: Black 1pt solid; text-align: center">August 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260531_zgI0dBRjMFi9" style="border-bottom: Black 1pt solid; text-align: center">May 31, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maIGzLcj_zMGnQ0hcZ7O4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,089,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,054,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--InventoryWorkInProcess_iI_maIGzLcj_zXfUdE8gVkp5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">648,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">868,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_maIGzLcj_z2Ix9qZAJPgj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Finished products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">267,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">179,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryGross_iTI_mtIGzLcj_maINzi6L_z27Dezufyfw2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total gross inventory</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,004,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,101,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryValuationReserves_iNI_di_msINzi6L_zaXXt6fm65ka" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Inventory reserves</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(370,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(394,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--InventoryNet_iTI_mtINzi6L_ztGth2eGIei2" style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal"> <td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left">Net inventory</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right">1,634,000</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right">1,707,000</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td></tr> </table> Reserves for inventory obsolescence are recognized as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory. As of August 31, 2026, and May 31, 2026, inventory reserves were approximately $370,000 and $394,000, respectively.

Net inventories are comprised of approximately the following: SCHEDULE OF NET INVENTORIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-right: 1in; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260831_z2fx8qfBzt27" style="border-bottom: Black 1pt solid; text-align: center">August 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260531_zgI0dBRjMFi9" style="border-bottom: Black 1pt solid; text-align: center">May 31, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maIGzLcj_zMGnQ0hcZ7O4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,089,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,054,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--InventoryWorkInProcess_iI_maIGzLcj_zXfUdE8gVkp5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">648,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">868,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_maIGzLcj_z2Ix9qZAJPgj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Finished products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">267,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">179,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryGross_iTI_mtIGzLcj_maINzi6L_z27Dezufyfw2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total gross inventory</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,004,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,101,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryValuationReserves_iNI_di_msINzi6L_zaXXt6fm65ka" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Inventory reserves</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(370,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(394,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--InventoryNet_iTI_mtINzi6L_ztGth2eGIei2" style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal"> <td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left">Net inventory</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right">1,634,000</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right">1,707,000</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td></tr> </table>

1089000

1054000

648000

868000

267000

179000

2004000

2101000

370000

394000

1634000

1707000

370000

394000

PROPERTY AND EQUIPMENT, NET Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired, or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income. Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense related to property and equipment was approximately $<span id="xdx_90C_eus-gaap--DepreciationDepletionAndAmortization_c20260601__20260831__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zjWoaFqG6h87" title="Depreciation and amortization expense">10,000 and $<span id="xdx_901_eus-gaap--DepreciationDepletionAndAmortization_c20250601__20250831__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zTykqN8yvFb7" title="Depreciation and amortization expense">15,000 for the three months ended August 31, 2026 and 2025, respectively.

P5Y

P10Y

10000

15000

INTANGIBLE ASSETS, NET Intangible assets include trademarks, product rights, technology rights, and patents, and are accounted for in accordance with ASC 350, Intangibles—Goodwill and Other. Intangible assets with indefinite useful lives are not amortized but are tested annually for impairment, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Intangible assets with finite useful lives are amortized using the straight-line method over their estimated useful lives, not to exceed <span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260831__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--MarketingAndDistributionRightsMember_zuhh2lfcWFyf" title="Intangible assets estimated useful lives">18 years for marketing and distribution rights and <span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260831__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedTechnologyRightsMember_zSbdRrGrOyaa" title="Intangible assets estimated useful lives">10 years for purchased technology rights. Patents are amortized over their respective estimated useful lives, which average approximately <span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260831__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zjn8NlJebbD5" title="Intangible assets estimated useful lives">15 years. Amortization expense was approximately $5,000 for the three months ended August 31, 2026, and 2025, respectively. Amortizing intangible assets are tested for impairment if management determines that events or changes in circumstances indicate that the asset might be impaired. We assess the recoverability of finite-lived intangible assets under ASC 360 by determining whether the carrying value of the applicable asset group can be recovered through projected undiscounted future cash flows. If the carrying amount is not recoverable, an impairment loss is recognized for the amount by which the carrying amount exceeds fair value. During the three months ended August 31, 2026 and 2025, no impairment charges were recognized.

P18Y

P10Y

P15Y

5000

INVESTMENTS We have made investments in a privately held Polish distributor, which is primarily engaged in distributing medical products and devices, including the distribution of the products sold by us. We invested approximately $165,000 into the Polish distributor and own approximately <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20260831__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PolishDistributorMember_zYhCAli5W7d3" title="Equity method investment, ownership percentage">6% of the Polish distributor. Equity holdings in nonmarketable unconsolidated entities in which we are not able to exercise significant influence are accounted for under the measurement alternative in ASC 321 at our initial cost, minus any impairment, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar securities of the same issuer. Dividends received are recognized in dividend, interest, and other income. We assess our equity holdings for impairment whenever events or changes in circumstances indicate that the carrying value of an equity holding may not be recoverable. Management reviewed the underlying net assets of our equity holding as of August 31, 2026 and determined that our proportionate economic interest in the entity indicates that the equity holding was not impaired. There were no observable price changes in orderly transactions for identical or similar security of the same issuer during the three months ended August 31, 2026 and August 31, 2025. On May 29, 2026, we entered into a SPA to sell our entire investment in Diagnosis S.A. for an aggregate purchase price of $500,000 in a related-party transaction involving our Chief Executive Officer and other purchasers. During the year ended May 31, 2026, we increased the carrying amount of the investment from approximately $165,000 to $500,000 and recognized an unrealized holding gain of approximately $335,000 based on the executed SPA. Pending completion of the applicable share transfers and required procedures under Polish law, we received $500,000 in cash and issued a secured promissory term note to our Chief Executive Officer. The note bears interest at <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20260531__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PolishDistributorMember_zaQctoTQ4uLb" title="Equity method investment, ownership percentage">8% per annum, matures on May 29, 2027, and is secured by our rights and interests in the Diagnosis S.A. shares. As of August 31, 2026, the share transfer had not been completed, and we continued to recognize the investment and the related note payable. The share transfer remains in process, subject to completion of the applicable procedures required under Polish law. As of August 31, 2026, the carrying amount of our investment in Diagnosis S.A. was approximately $500,000. Cumulative upward adjustments were approximately $335,000, and no cumulative impairment or downward adjustments had been recognized as of August 31, 2026.

165000

0.06

500000

165000

500000

335000

500000

0.08

500000

335000

SHARE-BASED COMPENSATION We follow the guidance of ASC 718, Share-based Compensation, which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments. Restricted stock awards are measured at grant-date fair value based on the fair value of our common stock. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model with assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. We have not paid dividends historically and do not expect to pay them in the foreseeable future. Expected volatilities are based on weighted averages of the historical volatility of our common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term as historically we had limited exercise activity surrounding our options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. The grant date fair value of the award is recognized under the straight-line attribution method. The following summary presents the options granted, exercised, expired, cancelled and outstanding for the three months ended August 31, 2026: SUMMARY OF OPTIONS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-style: normal; font-weight: normal"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Option Shares</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal"> <td style="font-style: normal; width: 60%; font-weight: normal">Options Outstanding at May 31, 2026</td><td style="font-style: normal; width: 2%; font-weight: normal"> </td> <td style="font-style: normal; width: 1%; font-weight: normal; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260601__20260831_z63N54aW47va" style="font-style: normal; width: 16%; font-weight: normal; text-align: right" title="Option Shares, Option outstanding, beginning balance">454,384</td><td style="font-style: normal; width: 1%; font-weight: normal; text-align: left"> </td><td style="font-style: normal; width: 2%; font-weight: normal"> </td> <td style="font-style: normal; width: 1%; font-weight: normal; text-align: left">$</td><td style="font-style: normal; width: 16%; font-weight: normal; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260601__20260831_zHqxklH4qaBj" style="font-style: normal; font-weight: normal">16.88</td><td style="font-style: normal; width: 1%; font-weight: normal; text-align: left"> </td></tr> <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal"> <td style="font-style: normal; text-align: left; padding-bottom: 1pt; font-weight: normal">Canceled or expired</td><td style="font-style: normal; padding-bottom: 1pt; font-weight: normal"> </td> <td style="border-bottom: Black 1pt solid; font-style: normal; text-align: left; font-weight: normal"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20260601__20260831_zoUBzp6gm8z1" style="border-bottom: Black 1pt solid; font-style: normal; text-align: right; font-weight: normal" title="Option Shares, Cancelled or expired">(25,001</td><td style="font-style: normal; padding-bottom: 1pt; text-align: left; font-weight: normal">)</td><td style="font-style: normal; padding-bottom: 1pt; font-weight: normal"> </td> <td style="border-bottom: Black 1pt solid; font-style: normal; text-align: left; font-weight: normal"> </td><td style="border-bottom: Black 1pt solid; font-style: normal; text-align: right; font-weight: normal"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260601__20260831_zCWJK6zxWH7i" style="font-style: normal; font-weight: normal">10.64</td><td style="font-style: normal; padding-bottom: 1pt; text-align: left; font-weight: normal"> </td></tr> <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal"> <td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt">Options Outstanding at August 31, 2026</td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260601__20260831_zkpDHD3zOSDg" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Option Shares, Option outstanding, ending balance">429,383</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260601__20260831_zIG9T64fyGCd" style="font-style: normal; font-weight: normal">17.24</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td></tr> <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal"> <td style="font-style: normal; font-weight: normal; text-align: left; padding-bottom: 2.5pt">Options vested and exercisable at August 31, 2026</td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20260601__20260831_z6GN5KW1Tkal" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Option Shares, Options vested and exercisable, ending balance">284,394</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260601__20260831_z9QYYCBoqpm9" style="font-style: normal; font-weight: normal">24.14</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td></tr> </table> During the three months ended August 31, 2026, we recognized approximately $40,000 of share-based compensation expense related to stock options, compared to approximately $74,000 for the three months ended August 31, 2025. During the three months ended August 31, 2026, we also issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20260601__20260831__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zGExJwAtyZYb" title="Shares issued for consulting services">10,000 shares of common stock pursuant to a consulting agreement. The shares had an aggregate fair value of approximately $<span id="xdx_908_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_c20260601__20260831__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zKz3hsLywZZ4" title="Common stock issued for consultant services">21,000, which was recognized as a share-based compensation expense. <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20250601__20250831__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zzJFTZWReXjf" title="Shares issued for consulting services">No shares were issued for consulting services during the three months ended August 31, 2025. <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zNByCVjEWPg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following summary presents the restricted stock awards granted, vested, forfeited and outstanding for the three months ended August 31, 2026: SCHEDULE OF RSUs ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-style: normal; font-weight: normal"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Restricted Stock Awards</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: normal; width: 60%; font-weight: normal; text-align: left">Unvested Restricted Stock Awards at May 31, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20260601__20260831_zMV6QPYrWCAk" style="width: 16%; text-align: right" title="Restricted Stock Awards, Outstanding, beginning balance">168,437</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue_iS_c20260601__20260831_zfBf0szK1XYe" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding, beginning balance">2.57</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: normal; font-weight: normal">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20260601__20260831_z3hZT0evmah8" style="text-align: right" title="Restricted Stock Awards, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue_c20260601__20260831_z5b54mdBedn5" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: normal; padding-bottom: 1pt; font-weight: normal">Vested</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_pid_c20260601__20260831_zc8cgKwxHNwk" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted Stock Awards, Vested">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageVestDateFairValue_c20260601__20260831_zk6M2TmPdxij" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Vested">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal"> <td style="font-style: normal; font-weight: normal; text-align: left; padding-bottom: 2.5pt">Unvested Restricted Stock Awards at August 31, 2026</td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20260601__20260831_zkA3KUCsrsn6" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Stock Awards, Outstanding, ending balance">168,437</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue_iE_c20260601__20260831_zI1RCAF7R95c" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding, ending balance">2.57</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td></tr> </table> During the three months ended August 31, 2026, we recognized approximately $73,000 of share-based compensation expense related to restricted stock awards, compared to approximately $59,000 for the three months ended August 31, 2025.

The following summary presents the options granted, exercised, expired, cancelled and outstanding for the three months ended August 31, 2026: SUMMARY OF OPTIONS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-style: normal; font-weight: normal"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Option Shares</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal"> <td style="font-style: normal; width: 60%; font-weight: normal">Options Outstanding at May 31, 2026</td><td style="font-style: normal; width: 2%; font-weight: normal"> </td> <td style="font-style: normal; width: 1%; font-weight: normal; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260601__20260831_z63N54aW47va" style="font-style: normal; width: 16%; font-weight: normal; text-align: right" title="Option Shares, Option outstanding, beginning balance">454,384</td><td style="font-style: normal; width: 1%; font-weight: normal; text-align: left"> </td><td style="font-style: normal; width: 2%; font-weight: normal"> </td> <td style="font-style: normal; width: 1%; font-weight: normal; text-align: left">$</td><td style="font-style: normal; width: 16%; font-weight: normal; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260601__20260831_zHqxklH4qaBj" style="font-style: normal; font-weight: normal">16.88</td><td style="font-style: normal; width: 1%; font-weight: normal; text-align: left"> </td></tr> <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal"> <td style="font-style: normal; text-align: left; padding-bottom: 1pt; font-weight: normal">Canceled or expired</td><td style="font-style: normal; padding-bottom: 1pt; font-weight: normal"> </td> <td style="border-bottom: Black 1pt solid; font-style: normal; text-align: left; font-weight: normal"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20260601__20260831_zoUBzp6gm8z1" style="border-bottom: Black 1pt solid; font-style: normal; text-align: right; font-weight: normal" title="Option Shares, Cancelled or expired">(25,001</td><td style="font-style: normal; padding-bottom: 1pt; text-align: left; font-weight: normal">)</td><td style="font-style: normal; padding-bottom: 1pt; font-weight: normal"> </td> <td style="border-bottom: Black 1pt solid; font-style: normal; text-align: left; font-weight: normal"> </td><td style="border-bottom: Black 1pt solid; font-style: normal; text-align: right; font-weight: normal"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260601__20260831_zCWJK6zxWH7i" style="font-style: normal; font-weight: normal">10.64</td><td style="font-style: normal; padding-bottom: 1pt; text-align: left; font-weight: normal"> </td></tr> <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal"> <td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt">Options Outstanding at August 31, 2026</td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260601__20260831_zkpDHD3zOSDg" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Option Shares, Option outstanding, ending balance">429,383</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260601__20260831_zIG9T64fyGCd" style="font-style: normal; font-weight: normal">17.24</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td></tr> <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal"> <td style="font-style: normal; font-weight: normal; text-align: left; padding-bottom: 2.5pt">Options vested and exercisable at August 31, 2026</td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20260601__20260831_z6GN5KW1Tkal" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Option Shares, Options vested and exercisable, ending balance">284,394</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260601__20260831_z9QYYCBoqpm9" style="font-style: normal; font-weight: normal">24.14</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td></tr> </table>

454384

16.88

25001

10.64

429383

17.24

284394

24.14

40000

74000

10000

21000

<p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zNByCVjEWPg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following summary presents the restricted stock awards granted, vested, forfeited and outstanding for the three months ended August 31, 2026: SCHEDULE OF RSUs ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-style: normal; font-weight: normal"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Restricted Stock Awards</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: normal; width: 60%; font-weight: normal; text-align: left">Unvested Restricted Stock Awards at May 31, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20260601__20260831_zMV6QPYrWCAk" style="width: 16%; text-align: right" title="Restricted Stock Awards, Outstanding, beginning balance">168,437</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue_iS_c20260601__20260831_zfBf0szK1XYe" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding, beginning balance">2.57</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: normal; font-weight: normal">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20260601__20260831_z3hZT0evmah8" style="text-align: right" title="Restricted Stock Awards, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue_c20260601__20260831_z5b54mdBedn5" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: normal; padding-bottom: 1pt; font-weight: normal">Vested</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_pid_c20260601__20260831_zc8cgKwxHNwk" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted Stock Awards, Vested">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageVestDateFairValue_c20260601__20260831_zk6M2TmPdxij" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Vested">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal"> <td style="font-style: normal; font-weight: normal; text-align: left; padding-bottom: 2.5pt">Unvested Restricted Stock Awards at August 31, 2026</td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20260601__20260831_zkA3KUCsrsn6" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Stock Awards, Outstanding, ending balance">168,437</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue_iE_c20260601__20260831_zI1RCAF7R95c" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding, ending balance">2.57</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td></tr> </table>

168437

2.57

168437

2.57

73000

59000

REVENUE RECOGNITION We have various contracts with customers, and these contracts specify the recognition of revenue based on the nature of the transaction. Revenues from product sales are recognized at the time the product is shipped, customarily Freight on Board (“FOB”) shipping point, which is when control of the goods transfers and title passes to the customer. This applies to clinical lab products sold to domestic and international distributors, including hospitals, clinical laboratories, medical research institutions, medical schools, and pharmaceutical companies. Over-the-counter (“OTC”) products are sold directly to e-commerce customers and distributors, while physicians’ office products are sold to physicians and distributors. We generally do not allow returns except in cases of defective merchandise, and therefore, do not establish an allowance for returns. Additionally, we have contracts with customers that provide purchase discounts contingent on achieving specified sales volumes. These contracts are regularly evaluated, and we do not anticipate granting any discounts through the end of the contract period. For diagnostic testing services sold directly to patients or physician offices that require processing by a third-party CLIA-certified lab, we recognize revenue once the lab has completed the test results. For services related to contract manufacturing, revenue is recognized when the service has been performed. For certain contracts, revenue is recognized over time as services are performed, measured based on progress toward completion. As of August 31, 2026, we had approximately $47,000 in advances from domestic customers, which are prepayments on orders for future shipments. Disaggregation of revenue: The following is a breakdown of revenues according to markets to which the products are sold: SCHEDULE OF DISAGGREGATION REVENUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-right: 0.25in; margin-left: 0.25in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260601__20260831_zGzofferTau4" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250601__20250831_zv2dbjJ6QLRb" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ClinicalLabMember_zJIQWdZ9QdQf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Clinical lab</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">775,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,024,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OverTheCounteMember_zVl3aZibgGsc" style="vertical-align: bottom; background-color: White"> <td>Over-the-counter</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">291,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ContractManufacturingMember_zFH6kW9zVUdg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contract manufacturing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">197,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">192,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PhysiciansOfficeMember_zgbJXOQtTCW8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Physician’s office</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_ztJQage1a5y" style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal"> <td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal">Total</td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right">1,265,000</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right">1,380,000</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td></tr> </table> See Note 4 for additional information regarding geographic revenue concentrations.

47000

The following is a breakdown of revenues according to markets to which the products are sold: SCHEDULE OF DISAGGREGATION REVENUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-right: 0.25in; margin-left: 0.25in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260601__20260831_zGzofferTau4" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250601__20250831_zv2dbjJ6QLRb" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ClinicalLabMember_zJIQWdZ9QdQf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Clinical lab</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">775,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,024,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OverTheCounteMember_zVl3aZibgGsc" style="vertical-align: bottom; background-color: White"> <td>Over-the-counter</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">291,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ContractManufacturingMember_zFH6kW9zVUdg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contract manufacturing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">197,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">192,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PhysiciansOfficeMember_zgbJXOQtTCW8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Physician’s office</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_ztJQage1a5y" style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal"> <td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal">Total</td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right">1,265,000</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right">1,380,000</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td></tr> </table>

775000

1024000

291000

161000

197000

192000

2000

3000

1265000

1380000

SHIPPING AND HANDLING FEES We include shipping and handling fees billed to customers in net sales.

RESEARCH AND DEVELOPMENT Research and development costs are expensed as incurred. We recognized approximately $206,000 and $212,000 of research and development costs during the three months ended August 31, 2026 and August 31, 2025, respectively.

206000

212000

INCOME TAXES For the three months ended August 31, 2026 and 2025, we recognized income tax expense of approximately $6,000 and $3,000, respectively. These expenses consisted of state minimum taxes and miscellaneous foreign taxes. During the three months ended August 31, 2026, we had a net operating loss (“NOL”) that generated deferred tax assets for NOL carryforwards. Deferred income tax assets and liabilities are recognized for temporary differences between the financial statements and income tax carrying values using enacted tax rates expected to apply when such differences are expected to reverse. Due to uncertainties surrounding our ability to generate future taxable income and consequently realize such deferred income tax assets, we have determined that it is more likely than not that these deferred tax assets will not be realized. Accordingly, we have maintained a full valuation allowance against the Company’s net deferred tax assets as of August 31, 2026. Our policy is to recognize any interest and penalties related to unrecognized tax benefits as a component of income tax expense. As of August 31, 2026, we had no accrued interest or penalties related to uncertain tax positions.

6000

3000

ADVERTISING COSTS We report the cost of advertising as an expense in the period in which those costs are incurred. For the three months ended August 31, 2026, and August 31, 2025, advertising costs were approximately $8,000 and $9,000, respectively.

8000

9000

FOREIGN CURRENCY TRANSLATION Biomerica de Mexico, our subsidiary located in Mexico, operates primarily using the Mexican peso. BioEurope GmbH, our subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring in euros. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the period, and revenues and costs are translated using average exchange rates for the period. The resulting translation adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no foreign currency transactions that are included in the condensed consolidated statements of operations and comprehensive loss for the three months ended August 31, 2026 and August 31, 2025.

RIGHT-OF-USE ASSETS AND LEASE LIABILITIES We account for our leases in accordance with ASC 842, Leases. We lease office space and copy machines, all of which are operating leases. Most leases include the option to renew and the exercise of the renewal options is at our sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise. Our leases do not include the options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited by the expected lease term.

NET (LOSS) INCOME PER SHARE Basic net (loss) income per share is computed as net (loss) income divided by the weighted-average number of common shares outstanding for the period. Diluted (loss) income per share reflects the potential dilution that could occur from common shares issuable upon the vesting of restricted stock units and from the exercise of stock options, and warrants using the treasury stock method, and from convertible securities using the if-converted method. The following potentially dilutive securities were excluded from the calculation of diluted (loss) income per share because their effect would have been anti-dilutive: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Stock options of 429,383 and 413,146 as of August 31, 2026 and 2025, respectively; and</td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Restricted stock units of 168,437 and 96,875 as of August 31, 2026 and 2025, respectively</td> </tr> </table>

429383

413146

168437

96875

SEGMENT REPORTING We define our segments on the basis in which internally reported financial information is reviewed by the Chief Operating Decision Maker (the “CODM”) to analyze financial performance, make decisions, and allocate resources. We manage our operations as a 1single operating and reportable segment, which focuses on the development, manufacture, marketing, and sale of diagnostic products. As all material financial information is included in the consolidated results we have identified one reportable segment. The CODM uses net (loss) income and cash flow information to evaluate performance, including detailed cost information as part of the budget and forecasting process and considers budget-to-actual variances on a regular basis when making decisions about the allocation of operating and capital resources. We measure segment profit or loss in net (loss) income as reported in the consolidated financial statements. The accounting policies used in the segment reporting are the same as those described in the summary of significant accounting policies. Our CODM is the Chief Executive Officer.

RECENT ACCOUNTING PRONOUNCEMENTS In November 2024, the FASB issued ASU 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40)”. The ASU includes enhanced disclosure requirements, which mandate enhanced transparency in financial statements by requiring detailed disclosures of specific expenses like inventory purchases, employee compensation, depreciation, and intangible asset amortization. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures. In July 2025, the FASB issued Update ASU 2025-05, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets”. This ASU provides targeted amendments to clarify the measurement of expected credit losses for accounts receivable and contract assets and introduces a practical expedient and related accounting policy election for certain entities. The amendments are effective for annual reporting periods beginning after December 15, 2025, including interim reporting periods within those annual reporting periods, with early adoption permitted. We adopted ASU 2025-05 effective June 1, 2026. The adoption did not have a material impact on our consolidated financial statements or related disclosures. In December 2025, the FASB issued Update ASU 2025-11, “Interim Reporting (Topic 270): Narrow-Scope Improvements”. This ASU clarifies and improves existing interim reporting guidance by consolidating disclosure requirements within Topic 270 and introducing a disclosure principle requiring entities to disclose events and changes occurring after the most recent annual reporting period that are expected to have a material effect on the entity’s financial condition or results of operations. The ASU does not introduce significant changes to recognition or measurement guidance. The amendments in this Update are effective for interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures.

NOTE 3: SHAREHOLDERS’ EQUITY On September 28, 2023, we filed the Shelf Registration allowing us to issue up to $20,000,000 of equity value in shares of common stock. Under the Shelf Registration Statement, shares of our common stock may be sold from time to time for up to three years from its initial effective date. On May 10, 2024, we filed a prospectus supplement to the Shelf Registration Statement with the SEC. This prospectus supplement was intended to facilitate the sale of up to $5,500,000 in common stock through the 2024 ATM Offering. The Shelf Registration Statement reached its third anniversary on September 29, 2026. See Note 7 for information regarding the filing of a replacement shelf registration statement. During the three months ended August 31, 2026, we did not sell any shares of common stock pursuant to the 2024 ATM Offering. On August 26, 2026, we completed a private placement pursuant to a SPA with accredited investors and issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260601__20260831__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_zNkbPfdDSKm3" title="Stock issued during period, shares, new issues">1,393,705 shares of our common stock at $1.60 per share, which resulted in gross proceeds of approximately $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20260601__20260831__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_z2N0NKBrqbmh" title="Sale of stock, consideration received on transaction">2,231,000 and net proceeds to us of $2,120,000 after deducting legal and other offering costs totaling approximately $111,000. The approximately $111,000 of offering costs were accrued and unpaid as of August 31, 2026. Accordingly, the gross proceeds were received in cash, while the offering costs reduced the net equity proceeds recorded.

20000000 5500000

1393705

1.60

2231000

2120000

111000

NOTE 4: GEOGRAPHIC INFORMATION We operate as one segment. Geographic information regarding net sales is approximately as follows: SCHEDULE OF GEOGRAPHIC INFORMATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenues from sales to unaffiliated customers:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 36%">Asia</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_c20260601__20260831__srt--StatementGeographicalAxis__srt--AsiaMember_zuaQjtqJ9Ub3" style="width: 12%; text-align: right" title="Revenues">467,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_ecustom--PercentageOfTotalRevenues_dp_uPure_c20260601__20260831__srt--StatementGeographicalAxis__srt--AsiaMember_z2Yv4k9j6Nu4" style="width: 12%; text-align: right" title="Percentage of total revenue">37</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--Revenues_c20250601__20250831__srt--StatementGeographicalAxis__srt--AsiaMember_zedCckCMhFOa" style="width: 12%; text-align: right" title="Revenues">670,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_ecustom--PercentageOfTotalRevenues_dp_uPure_c20250601__20250831__srt--StatementGeographicalAxis__srt--AsiaMember_zuTpajEDlhKc" style="width: 12%; text-align: right" title="Percentage of total revenue">49</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">North America</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--Revenues_c20260601__20260831__srt--StatementGeographicalAxis__srt--NorthAmericaMember_zN9EdXXeJosj" style="text-align: right" title="Revenues">379,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--PercentageOfTotalRevenues_dp_uPure_c20260601__20260831__srt--StatementGeographicalAxis__srt--NorthAmericaMember_zrbqs2DPl5u8" style="text-align: right" title="Percentage of total revenue">30</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--Revenues_c20250601__20250831__srt--StatementGeographicalAxis__srt--NorthAmericaMember_zRKE08ecHe5h" style="text-align: right" title="Revenues">318,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--PercentageOfTotalRevenues_dp_uPure_c20250601__20250831__srt--StatementGeographicalAxis__srt--NorthAmericaMember_zW0oOkDyEh5j" style="text-align: right" title="Percentage of total revenue">23</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Europe</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--Revenues_c20260601__20260831__srt--StatementGeographicalAxis__srt--EuropeMember_zOfoiAJS4MQi" style="text-align: right" title="Revenues">284,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--PercentageOfTotalRevenues_dp_uPure_c20260601__20260831__srt--StatementGeographicalAxis__srt--EuropeMember_zXSg8NY01qp8" style="text-align: right" title="Percentage of total revenue">22</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--Revenues_c20250601__20250831__srt--StatementGeographicalAxis__srt--EuropeMember_zD5gFUnd9cc2" style="text-align: right" title="Revenues">305,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--PercentageOfTotalRevenues_dp_uPure_c20250601__20250831__srt--StatementGeographicalAxis__srt--EuropeMember_zzMFsu3aFuQ1" style="text-align: right" title="Percentage of total revenue">22</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Middle East</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--Revenues_c20260601__20260831__srt--StatementGeographicalAxis__us-gaap--MiddleEastMember_zCKN7NGg7hPg" style="text-align: right" title="Revenues">135,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--PercentageOfTotalRevenues_dp_uPure_c20260601__20260831__srt--StatementGeographicalAxis__us-gaap--MiddleEastMember_zLcBGROvtX0l" style="text-align: right" title="Percentage of total revenue">11</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--Revenues_c20250601__20250831__srt--StatementGeographicalAxis__us-gaap--MiddleEastMember_zR40Hx3bX0Tj" style="text-align: right" title="Revenues">85,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--PercentageOfTotalRevenues_dp_uPure_c20250601__20250831__srt--StatementGeographicalAxis__us-gaap--MiddleEastMember_z7jazNnAEeW9" style="text-align: right" title="Percentage of total revenue">6</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">South America</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--Revenues_c20260601__20260831__srt--StatementGeographicalAxis__srt--SouthAmericaMember_zM5pXuwp1K11" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98F_ecustom--PercentageOfTotalRevenues_dp_uPure_c20260601__20260831__srt--StatementGeographicalAxis__srt--SouthAmericaMember_zocoS0mD22yk" style="padding-bottom: 1pt; text-align: right" title="Percentage of total revenue">0</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--Revenues_c20250601__20250831__srt--StatementGeographicalAxis__srt--SouthAmericaMember_zpF3DAsaZKTi" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">2,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98E_ecustom--PercentageOfTotalRevenues_dp_uPure_c20250601__20250831__srt--StatementGeographicalAxis__srt--SouthAmericaMember_zXlOE5GVO6n1" style="padding-bottom: 1pt; text-align: right" title="Percentage of total revenue">0</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal"> <td style="font-style: normal; padding-left: 10pt; font-weight: normal; padding-bottom: 2.5pt">Total</td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_98D_eus-gaap--Revenues_c20260601__20260831_zK6lv60knpuh" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Revenues">1,265,000</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal"> </td> <td style="font-style: normal; padding-bottom: 2.5pt; text-align: left; font-weight: normal"> </td><td style="font-style: normal; padding-bottom: 2.5pt; text-align: right; font-weight: normal"> </td><td style="font-style: normal; padding-bottom: 2.5pt; text-align: left; font-weight: normal"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_c20250601__20250831_zqRD18Ipa3Lb" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Revenues">1,380,000</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal"> </td> <td style="font-style: normal; padding-bottom: 2.5pt; text-align: left; font-weight: normal"> </td><td style="font-style: normal; padding-bottom: 2.5pt; text-align: right; font-weight: normal"> </td><td style="font-style: normal; padding-bottom: 2.5pt; text-align: left; font-weight: normal"> </td></tr> </table> As of August 31, 2026, and May 31, 2026, approximately $559,000 and $517,000 of our gross inventory was located in Mexicali, Mexico, respectively. As of August 31, 2026, and May 31, 2026, approximately $6,000 and $8,000 of our property and equipment, net of accumulated depreciation and amortization, was located in Mexicali, Mexico, respectively.

SCHEDULE OF GEOGRAPHIC INFORMATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenues from sales to unaffiliated customers:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 36%">Asia</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_c20260601__20260831__srt--StatementGeographicalAxis__srt--AsiaMember_zuaQjtqJ9Ub3" style="width: 12%; text-align: right" title="Revenues">467,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_ecustom--PercentageOfTotalRevenues_dp_uPure_c20260601__20260831__srt--StatementGeographicalAxis__srt--AsiaMember_z2Yv4k9j6Nu4" style="width: 12%; text-align: right" title="Percentage of total revenue">37</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--Revenues_c20250601__20250831__srt--StatementGeographicalAxis__srt--AsiaMember_zedCckCMhFOa" style="width: 12%; text-align: right" title="Revenues">670,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_ecustom--PercentageOfTotalRevenues_dp_uPure_c20250601__20250831__srt--StatementGeographicalAxis__srt--AsiaMember_zuTpajEDlhKc" style="width: 12%; text-align: right" title="Percentage of total revenue">49</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">North America</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--Revenues_c20260601__20260831__srt--StatementGeographicalAxis__srt--NorthAmericaMember_zN9EdXXeJosj" style="text-align: right" title="Revenues">379,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--PercentageOfTotalRevenues_dp_uPure_c20260601__20260831__srt--StatementGeographicalAxis__srt--NorthAmericaMember_zrbqs2DPl5u8" style="text-align: right" title="Percentage of total revenue">30</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--Revenues_c20250601__20250831__srt--StatementGeographicalAxis__srt--NorthAmericaMember_zRKE08ecHe5h" style="text-align: right" title="Revenues">318,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--PercentageOfTotalRevenues_dp_uPure_c20250601__20250831__srt--StatementGeographicalAxis__srt--NorthAmericaMember_zW0oOkDyEh5j" style="text-align: right" title="Percentage of total revenue">23</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Europe</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--Revenues_c20260601__20260831__srt--StatementGeographicalAxis__srt--EuropeMember_zOfoiAJS4MQi" style="text-align: right" title="Revenues">284,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--PercentageOfTotalRevenues_dp_uPure_c20260601__20260831__srt--StatementGeographicalAxis__srt--EuropeMember_zXSg8NY01qp8" style="text-align: right" title="Percentage of total revenue">22</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--Revenues_c20250601__20250831__srt--StatementGeographicalAxis__srt--EuropeMember_zD5gFUnd9cc2" style="text-align: right" title="Revenues">305,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--PercentageOfTotalRevenues_dp_uPure_c20250601__20250831__srt--StatementGeographicalAxis__srt--EuropeMember_zzMFsu3aFuQ1" style="text-align: right" title="Percentage of total revenue">22</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Middle East</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--Revenues_c20260601__20260831__srt--StatementGeographicalAxis__us-gaap--MiddleEastMember_zCKN7NGg7hPg" style="text-align: right" title="Revenues">135,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--PercentageOfTotalRevenues_dp_uPure_c20260601__20260831__srt--StatementGeographicalAxis__us-gaap--MiddleEastMember_zLcBGROvtX0l" style="text-align: right" title="Percentage of total revenue">11</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--Revenues_c20250601__20250831__srt--StatementGeographicalAxis__us-gaap--MiddleEastMember_zR40Hx3bX0Tj" style="text-align: right" title="Revenues">85,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--PercentageOfTotalRevenues_dp_uPure_c20250601__20250831__srt--StatementGeographicalAxis__us-gaap--MiddleEastMember_z7jazNnAEeW9" style="text-align: right" title="Percentage of total revenue">6</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">South America</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--Revenues_c20260601__20260831__srt--StatementGeographicalAxis__srt--SouthAmericaMember_zM5pXuwp1K11" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98F_ecustom--PercentageOfTotalRevenues_dp_uPure_c20260601__20260831__srt--StatementGeographicalAxis__srt--SouthAmericaMember_zocoS0mD22yk" style="padding-bottom: 1pt; text-align: right" title="Percentage of total revenue">0</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--Revenues_c20250601__20250831__srt--StatementGeographicalAxis__srt--SouthAmericaMember_zpF3DAsaZKTi" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">2,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98E_ecustom--PercentageOfTotalRevenues_dp_uPure_c20250601__20250831__srt--StatementGeographicalAxis__srt--SouthAmericaMember_zXlOE5GVO6n1" style="padding-bottom: 1pt; text-align: right" title="Percentage of total revenue">0</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal"> <td style="font-style: normal; padding-left: 10pt; font-weight: normal; padding-bottom: 2.5pt">Total</td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_98D_eus-gaap--Revenues_c20260601__20260831_zK6lv60knpuh" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Revenues">1,265,000</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal"> </td> <td style="font-style: normal; padding-bottom: 2.5pt; text-align: left; font-weight: normal"> </td><td style="font-style: normal; padding-bottom: 2.5pt; text-align: right; font-weight: normal"> </td><td style="font-style: normal; padding-bottom: 2.5pt; text-align: left; font-weight: normal"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_c20250601__20250831_zqRD18Ipa3Lb" style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right" title="Revenues">1,380,000</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal"> </td> <td style="font-style: normal; padding-bottom: 2.5pt; text-align: left; font-weight: normal"> </td><td style="font-style: normal; padding-bottom: 2.5pt; text-align: right; font-weight: normal"> </td><td style="font-style: normal; padding-bottom: 2.5pt; text-align: left; font-weight: normal"> </td></tr> </table>

467000

0.37

670000

0.49

379000

0.30

318000

0.23

284000

0.22

305000

0.22

135000

0.11

85000

0.06 0

2000

1265000

1380000

559000

517000

6000

8000

NOTE 5: LEASES We lease facilities in Irvine, California and Mexicali, Mexico. As of August 31, 2026, we had approximately 22,000 square feet of floor space at our corporate headquarters at 17571 Von Karman Avenue in Irvine, California, which we have been leasing since 2009. This facility includes administration, research and development, certain manufacturing, shipping and inventory storage. In May 2026, we exercised the additional five-year extension option and entered into a lease extension agreement with the landlord, extending the lease for an additional five-year term commencing September 1, 2026, and expiring August 31, 2031. The monthly base rent at the commencement of the extended term is approximately $28,400 and is subject to scheduled increases during the lease term. In November 2016, our Mexican subsidiary, Biomerica de Mexico, entered into a 10-year lease for approximately 8,100 square feet of manufacturing space located in Mexicali, Mexico. The lease includes an option to renew for an additional 10-year term. As of May 31, 2026, management determined that exercise of the renewal option was reasonably certain and, accordingly, the additional 10-year renewal period was included in the lease term used to measure the related right-of-use asset and lease liability. As of August 31, 2026, documentation formalizing the renewal had not yet been executed with the landlord. The current rent is approximately $4,300 per month. Biomerica de Mexico also leases a smaller unit on a month-to-month basis for use in one manufacturing process. In addition, we lease a small office in Lindau, Germany on a month-to-month basis, which serves as the headquarters of BioEurope GmbH, our German subsidiary. For purposes of determining straight-line rent expense, the lease term is calculated from the date we first take possession of the facility, including any periods of free rent and any renewal option periods that we are reasonably certain to exercise. Our office and equipment leases generally have contractually specified minimum rent, and annual rent increases are included in the measurement of the right-of-use asset and related lease liabilities. Additionally, under these lease arrangements, we may be required to pay directly, or reimburse the lessors, for certain maintenance and operating costs. Such amounts are generally variable and, therefore, not included in the measurement of the right-of-use asset and related lease liabilities but are instead recognized as variable lease expense in the condensed consolidated statements of operations and comprehensive loss when they are incurred. The following table presents information on our operating leases for the three months ended August 31, 2026 and August 31, 2025: SCHEDULE OF OPERATING LEASES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260601__20260831_zs7gi9ZYzn9i" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20250601__20250831_zor0COcUYMBd" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseCost_maLCzsjE_zcyKSSXDWCt4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Operating lease cost</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">104,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">88,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--VariableLeaseCost_maLCzsjE_zDOU1zAVFoSd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Variable lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ShortTermLeaseCost_maLCzsjE_zXGju0Tvk5lg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Short-term lease cost</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LeaseCost_iT_mtLCzsjE_zNJUnMZSGjve" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">107,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">91,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The maturities of operating lease liabilities as of August 31, 2026 are as follows: Year Ending May 31: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260831_zHH5LMPNcr1i" style="border-bottom: Black 1pt solid; text-align: center">Operating Leases</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzfjE_zUNn9Ub1DGp" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 80%; text-align: left; padding-bottom: 1pt">2027 (excluding the three months ended August 31, 2026)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">392,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzfjE_zlWXEeOOfSG2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">406,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzfjE_zc4To2054c6l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">420,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzfjE_zAweOQ6Vfrqk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">2030</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">434,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzfjE_zsQx8wiQQ2o6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">2031</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">450,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPzfjE_z27wO1pcp5I5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">266,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzfjE_zyMY3POe1By1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total minimum future lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,368,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_zsBbMNuvWGrl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">542,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iTI_zRWwgBCWLDR3" style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal"> <td style="font-style: normal; text-align: left; padding-bottom: 2.5pt; font-weight: normal">Total operating lease liabilities</td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right">1,826,000</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td></tr> </table> The following table summarizes our other supplemental lease information for the three months ended August 31, 2026 and August 31, 2025: SCHEDULE OF OTHER SUPPLEMENTAL LEASE INFORMATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20260601__20260831_zkD19fILTJC7" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20250601__20250831_zPO7orKWNsua" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeasePayments_z4RjBwvdvGA4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Cash paid for operating lease liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">98,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">92,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average remaining lease term (years)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260831_zTe8ALpzkJvk" style="text-align: right" title="Weighted-average remaining lease term (years)">5.98</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250831_zfdgzQg1iZ5j" style="text-align: right" title="Weighted-average remaining lease term (years)">1.02</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iE_pid_dp_za59vOA9H5rk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.78</td><td style="text-align: left">%</td></tr> </table> We also have various insignificant leases for office equipment.

22000

28400

In November 2016, our Mexican subsidiary, Biomerica de Mexico, entered into a 10-year lease for approximately 8,100 square feet of manufacturing space located in Mexicali, Mexico. The lease includes an option to renew for an additional 10-year term

P10Y

8100

P10Y

4300

SCHEDULE OF OPERATING LEASES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260601__20260831_zs7gi9ZYzn9i" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20250601__20250831_zor0COcUYMBd" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseCost_maLCzsjE_zcyKSSXDWCt4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Operating lease cost</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">104,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">88,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--VariableLeaseCost_maLCzsjE_zDOU1zAVFoSd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Variable lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ShortTermLeaseCost_maLCzsjE_zXGju0Tvk5lg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Short-term lease cost</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LeaseCost_iT_mtLCzsjE_zNJUnMZSGjve" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">107,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">91,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

104000

88000

2000

3000

1000

107000

91000

Year Ending May 31: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260831_zHH5LMPNcr1i" style="border-bottom: Black 1pt solid; text-align: center">Operating Leases</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzfjE_zUNn9Ub1DGp" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 80%; text-align: left; padding-bottom: 1pt">2027 (excluding the three months ended August 31, 2026)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">392,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzfjE_zlWXEeOOfSG2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">406,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzfjE_zc4To2054c6l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">420,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzfjE_zAweOQ6Vfrqk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">2030</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">434,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzfjE_zsQx8wiQQ2o6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">2031</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">450,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPzfjE_z27wO1pcp5I5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">266,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzfjE_zyMY3POe1By1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total minimum future lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,368,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_zsBbMNuvWGrl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">542,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iTI_zRWwgBCWLDR3" style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal"> <td style="font-style: normal; text-align: left; padding-bottom: 2.5pt; font-weight: normal">Total operating lease liabilities</td><td style="font-style: normal; font-weight: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; font-weight: normal; text-align: right">1,826,000</td><td style="font-style: normal; padding-bottom: 2.5pt; font-weight: normal; text-align: left"> </td></tr> </table>

392000

406000

420000

434000

450000

266000

2368000

542000

1826000

The following table summarizes our other supplemental lease information for the three months ended August 31, 2026 and August 31, 2025: SCHEDULE OF OTHER SUPPLEMENTAL LEASE INFORMATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20260601__20260831_zkD19fILTJC7" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20250601__20250831_zPO7orKWNsua" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeasePayments_z4RjBwvdvGA4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Cash paid for operating lease liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">98,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">92,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average remaining lease term (years)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260831_zTe8ALpzkJvk" style="text-align: right" title="Weighted-average remaining lease term (years)">5.98</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250831_zfdgzQg1iZ5j" style="text-align: right" title="Weighted-average remaining lease term (years)">1.02</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iE_pid_dp_za59vOA9H5rk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.78</td><td style="text-align: left">%</td></tr> </table>

98000

92000

P5Y11M23D

P1Y7D

0.0900

0.0578

NOTE 6: COMMITMENTS AND CONTINGENCIES LITIGATION We are, from time to time, involved in legal proceedings, claims, and litigation arising in the ordinary course of business. There were no material legal proceedings pending as of August 31, 2026.

NOTE 7: SUBSEQUENT EVENTS On September 24, 2026, we filed a registration statement on Form S-3 with the SEC covering the resale by selling stockholders of up to <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260924__20260924__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRV6LOppNX59" title="Shares issued">1,403,705 shares of our common stock, consisting of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260924__20260924__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zuqsrSixxaz3" title="Shares issued">1,393,705 shares issued in the August 2026 private placement (the “Private Placement”) and <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20260924__20260924__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zsDjcCEl3Vo8" title="Shares issued for consulting services">10,000 shares issued pursuant to a consulting agreement. We will not receive any proceeds from sales of these shares by the selling stockholders. The resale registration statement was filed pursuant to a Registration Rights Agreement entered into with the investors in connection with the Private Placement, which closed on August 26, 2026, under which we agreed to file a registration statement with the SEC covering the resale of the shares issued in the Private Placement and to use commercially reasonable efforts to cause it to become effective and remain effective for the periods specified therein. On September 24, 2026, we also filed a replacement shelf registration statement on Form S-3 with the SEC covering the offer and sale from time to time of common stock, preferred stock, debt securities and warrants with an aggregate offering price of up to $<span id="xdx_905_ecustom--ReplacementShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_c20260924__20260924__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOmv2D67OI63" title="Aggregate offering price">250,000,000, subject to applicable limitations under General Instruction I.B.6 of Form S-3. Both registration statements were declared effective by the SEC on October 7, 2026.

1403705

1393705

10000

250000000